Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01548651 · ClinicalTrials.gov registry record · Phase 4
Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation
A Phase 4 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT01548651 is a Phase 4 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT01548651, a Phase 4 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the effect of saxagliptin, an anti-diabetes medication, on hepatic and myocardial fat content and monocyte inflammation in patients with Impaired Glucose Tolerance (IGT).
Interventions
- DRUG Placebo
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-02 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01548651
The ClinicalTrials.gov registry entry for NCT01548651 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01548651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01548651 about?
NCT01548651 is a clinical study titled "Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation". The purpose of the study is to examine the effect of saxagliptin, an anti-diabetes medication, on hepatic and myocardial fat content and monocyte inflammation in patients with Impaired Glucose Tolerance (IGT).
What is the current status of trial NCT01548651?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2012-02. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT01548651?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT01548651?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.